Rail Vikas Nigam Declares Interim Dividend and Approves Financial Results

Rail Vikas Nigam (RVNL) announced its unaudited financial results for Q3 2025-26, showcasing a net profit after tax of ₹264.23 crore. The Board approved an interim dividend of ₹1 per share. The company has ongoing concerns regarding recoverables from Krishnapatnam Railway Company Limited (KRCL) and departmental charges waiver.

Financial Performance Highlights

For the quarter ended December 31, 2025, Rail Vikas Nigam (RVNL) reported a standalone net profit after tax of ₹264.23 crore. Total income for the quarter stood at ₹4,738.49 crore. The results reflect the company’s performance in the third quarter (Q3) of fiscal year 2025-26.

Interim Dividend Declaration

The Board of Directors has declared an interim dividend of ₹1.00 per share (10% of paid-up share capital). This dividend will be paid on or before March 6, 2026. The record date to determine shareholders’ eligibility for the dividend is set for February 11, 2026.

Key Financial Figures (Standalone)

Key figures from the Unaudited Standalone Financial Results include:

  • Revenue from Operations: ₹4,503.97 crore
  • Other Income: ₹234.52 crore
  • Total Expenses: ₹4,386.35 crore
  • Profit Before Tax: ₹352.14 crore
  • Auditor’s Emphasis: KRCL Matters

    The independent auditors have drawn attention to certain matters regarding Krishnapatnam Railway Company Limited (KRCL). As of December 31, 2025, the amount recoverable from KRCL is ₹1169.31 crore, inclusive of ₹889.95 crore in interest. Additionally, a claim for departmental charges at 5% of the project’s completion cost has not been raised on KRCL, pending a decision by the Board of Directors.

    Consolidated Results Overview

    The consolidated unaudited financial results reflect a net profit after tax of ₹324.14 crore. Consolidated total income reached ₹4,936.14 crore for the same period.

    Source: BSE

    Previous Article

    Rail Vikas Nigam Board Approves Interim Dividend of ₹1 Per Share

    Next Article

    Poly Medicure Q3 FY26 Consolidated Revenue Up 16.4%